Disease/Infection News

RSS

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection -- genotype 2 and 3, say a team of scientists led by Weill Cornell Medical College researchers.

25 Apr 2013

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

Researchers at the University of Cincinnati have found that targeted screening for populations with a higher estimated prevalence for hepatitis C may be cost-effective.

25 Apr 2013

WHO research team still unsure of H7N9 transmission routes

The WHO "has only a limited understanding of a deadly new form of avian flu that has killed 20 people and infected more than a hundred others, a team of researchers said on Monday, leaving unclear how the disease spreads and how virulent it could become," the Wall Street Journal reports.

24 Apr 2013

Supreme Court justices hear arguments in case challenging anti-prostitution pledge

"Supreme Court justices appeared divided on Monday as they considered a challenge to a law requiring non-profit organizations to adopt an anti-prostitution policy in order to obtain federal funding for HIV/AIDS programs abroad," Reuters reports (Hurley, 4/22).

24 Apr 2013

Research maps risk factors for transmission of animal brucellosis, BTB to humans

A new study at the Institute of Tropical Medicine in Antwerp analyses the impact of animal brucellosis and bovine tuberculosis on animals and people in urban, peri-urban and rural Niger.

24 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Editorial, opinion piece respond to Supreme Court case challenging anti-prostitution pledge

The U.S. Supreme Court on Monday heard a case -- AOSI v. USAID -- challenging a 2003 federal statute that requires non-profit organizations to adopt an "anti-prostitution policy" in order to receive federal funding for HIV/AIDS programs abroad, on the grounds that it violates the First Amendment.

24 Apr 2013

Study identifies malaria parasite protein as potential new target for drug treatment to prevent malaria

Scientists have discovered how a protein within the malaria parasite is essential to its survival as it develops inside a mosquito. They believe their findings identify this protein as a potential new target for drug treatments to prevent malaria being passed to humans.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

U.S. on the verge of potentially devastating epidemic of untreatable gonorrhea

Gonorrhea has long been one of the most commonly-reported sexually transmitted diseases (STDs) in the U.S. and, unfortunately, with rising antimicrobial resistance, it has also become one of the most frightening for public health.

24 Apr 2013

Home-based health education about diseases most effective, finds study

In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found.

24 Apr 2013

Rapid Assessment of Malaria device provides faster, more accurate diagnostic test

There, the pitch by company CEO John R. Lewandowski, who opened with the line, "What if I told you I could save one million lives every year with just refrigerator magnets and a laser pointer?", got raves and a replay on Fortune Magazine/CNN online.

24 Apr 2013

AfriCoLeish receives grant from European Union to test new treatments for kala-azar

Research and development (R&D) project, AfriCoLeish, is supported by the European Union Seventh Framework Programme (EU FP7) through a grant of -3 million. The project will run for three years and aims to test new treatments for kala-azar (visceral leishmaniasis, or VL) and co-infection of the disease with HIV in Ethiopia and Sudan.

23 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

World must be better prepared for potential pandemics

"In China an influenza virus never before seen in people had, as The Economist went to press, infected at least 82 and killed 17. Meanwhile a new type of coronavirus, the family that brought severe acute respiratory syndrome (SARS), is festering in the Middle East," an editorial in the magazine states.

23 Apr 2013

Research: Skin's immune cell plays a role in fighting off parasitic invaders

Sydney researchers have discovered a new type of immune cell in skin that plays a role in fighting off parasitic invaders such as ticks, mites, and worms, and could be linked to eczema and allergic skin diseases.

23 Apr 2013

First Edition: April 23, 2013

Today's headlines include reports about immigrant patients' health care as well as the coverage limits that some victims of the Boston Marathon bombings might face.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Disease/Infection News

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

Targeted screening for chronic hepatitis C virus infection is cost-effective, say researchers

WHO research team still unsure of H7N9 transmission routes

Supreme Court justices hear arguments in case challenging anti-prostitution pledge

Research maps risk factors for transmission of animal brucellosis, BTB to humans

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Editorial, opinion piece respond to Supreme Court case challenging anti-prostitution pledge

Study identifies malaria parasite protein as potential new target for drug treatment to prevent malaria

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

U.S. on the verge of potentially devastating epidemic of untreatable gonorrhea

Home-based health education about diseases most effective, finds study

Rapid Assessment of Malaria device provides faster, more accurate diagnostic test

AfriCoLeish receives grant from European Union to test new treatments for kala-azar

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

World must be better prepared for potential pandemics

Research: Skin's immune cell plays a role in fighting off parasitic invaders

First Edition: April 23, 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News